Cannabidiol oil for decreasing addictive use of marijuana: A case report

Integrative Medicine (Boulder)

Volumn 14, Issue 6, 2015, Pages 31-35

  Shannon, Scott ^a   Opila Lehman, Janet ^a  

^a Wholeness Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016251159     PISSN: 1546993X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlinie EA. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol. 1974; 28(1):172-177.
2. Dalton WS, Martz R, Lemberger L, Rodda BE, Forney RG. Influence of cannabidiol on delta 9-tetrahydrocannabinol effects. Clin Pharmacol Ther. 1976; 19(3):300-309.
3. Campos AC, Moreira FA, Gomes FV, DelBel EA, Guimaraes FS. Multiple mechanism involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Phil Trans R Soc B. 2012; 367(1607):3364-3378.
4. GW Pharmaceuticals. Research papers. http://www.gwpharm.com/publications-1.aspx. Published 2014. Accessed December 15, 2015.
5. McPartland JM, Guy G. The evolution of Cannabis and coevolution with the cannabinoid receptor: A hypothesis. In: Guy G, Robson R, Strong K, Whittle B, eds. The Medicinal Use of Cannabis. London, United Kingdom: Royal Society of Pharmacists; 2004:71-102.
6. Leweke FM, Piomelli D, Pahlisch F, Muhi D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012; 20(2):e94.
7. Lee MA. How CBD works. Project CBD Website. https://www.projectcbd.org. Accessed November 20, 2015.
8. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. J Psychopharmacol. 2011; 25(1):121-130.
9. Ross RA. Modulation of human neutrophil migration by endocannabinoids and phytocannabinoids: Evidence for a site distinct from CB1 and CB2. Mol Pharmacol. 2008; 73(2):1-10.
10. Zhornitsky S, Potvin S. Cannabidiol in humans: The quest for therapeutic targets. Pharmaceuticals. 2012; 5(5):529-552.
11. Zuardi AW. Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008; 30(3):271-280.
12. Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorg Med Chem. 2015; 23(7):1377-1385.
13. Fernandez-Ruiz J, Sagredo O, Pazos MR, et al. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid. Br J Clin Pharmacol. 2013; 75(2):323-333.
14. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol a Cannabis sativa constituent as an antipsychotic drug. Braz J Med Biol Res. 2006; 39(4):421-429.
15. International Cannabinoid Research Society. Program for 25th annual symposium. http://www.icrs.co/SYMPOSIUM.2015/ICRS2015.Programme. pdf. Published June-July 2015. Accessed December 15, 2015.
16. Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, Chagas MH, Zuardi AW. Cannabidiol for the treatment of cannabis withdrawal syndrome: A case report. J Clin Pharm Ther. 2013; 28(2):162-164.
17. University of Pittsburgh. University of Pittsburgh Sleep Medicine Institute Pittsburgh Sleep Quality Index (PSQI). http://www.sleep.pitt.edu/content. Accessed November 20, 2015.
18. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32(1):50-55.
19. Prud'home M, Cata R, Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: A systematic review of the evidence. Res Treat. May 2015; 9:33-38.
20. Haney M. The marijuana withdrawal syndrome: Diagnosis and treatment. Curr Psychiatry Rep. 2005; 7(5):360-366.